Published online before print October 24, 2002, doi: 10.1161/01.ATV.0000043452.30772.18
© 2002 American Heart Association, Inc.
Brief Reviews |
The Reactive Adventitia
Fibroblast Oxidase in Vascular Function
From the Hypertension and Vascular Research Division (P.J.P.), Henry Ford Hospital, Detroit, Michigan, and the Department of Microbiology (F.E.R.), University of Iowa, Iowa City.
Correspondence to Patrick J. Pagano, PhD, Room7044, E&R Building, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202-2689. E-mail ppagano1{at}hfhs.org
 |
Abstract |
|---|
 Top Abstract IntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
The vascular adventitia is activated in a variety of cardiovascular disease states and has recently been shown to be a barrier to nitric oxide bioactivity. Vascular fibroblasts produce substantial amounts of NAD(P)H oxidase–derived reactive oxygen species (ROS) that appear to be involved in fibroblast proliferation, connective tissue deposition, and perhaps vascular tone. However, the physiological and pathophysiological roles of the adventitia have not been extensively studied, possibly because of its location in large blood vessels remote from the vascular endothelium. In recent years, substantial information has been gathered on pathways leading to oxidase activation in smooth muscle cells and fibroblasts and the downstream signaling pathways leading to hypertrophy and proliferation. A clearer understanding of the molecular mechanisms involved will likely lead to therapeutic strategies aimed at preventing vascular dysfunction in diseases such as atherosclerosis, in which these pathways are activated.
Key Words: NAD(P)H oxidase • NADPH oxidoreductase • fibroblast • vascular smooth muscle • adventitia • remodeling
|
Introduction |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
The contribution of the adventitia to vascular function has largely been ignored, except for an occasional mention that it provides support for the blood vessel (extracellular matrix) and a scaffold for sympathetic nerve endings and the vasa vasorum. Much attention has been given to the vascular endothelium in the past 20 years since the discovery of endothelium-derived relaxing factor (EDRF), but before that, it was held in the same disregard as the adventitia, considered merely a physical barrier separating tissues. The adventitia is defined as "the outermost connective tissue of any organ, vessel, or other structure not covered by a serosa; instead, the covering is properly derived from without ... and does not form an integral part of such organ or structure"1 and is derived from the Latin adventicius, or "coming from abroad, foreign." Thus, given its "outsider" status, it is no surprise that the adventitia has not been given substantial consideration. In recent years, several important studies have lent credence to the concept that functional changes in the adventitia lead to vascular pathology. The rapid growth of the field of reactive oxygen species (ROS) and the realization that these species can act as tissue-signaling agents have brought new significance to the role of the adventitia in vascular function. Hopefully, this review may dispel some of the obscurity clouding this important tissue.
|
Anatomy of a Blood Vessel |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
The most commonly studied arterial segments are (1) the tunica intima, consisting of a longitudinal endothelial lining and, in some vessels, containing delicate connective tissue with occasional smooth muscle cells (SMCs) and (2) the tunica media, made up of circumferentially arranged SMCs and, depending on its size, a well-developed elastic net. The third segment, called the tunica adventitia, is composed primarily of fibroblasts, collagen, and elastin fibers oriented longitudinally. A variety of other cells, including mast cells, macrophages, and ganglionic cells, are also present. The relative size of the 3 segments varies depending on the size of the artery. Interestingly, medial thickness ranges from 3 or 4 smooth muscle layers in small arteries to 40 in large arteries.2 The boundary between the intima and media is demarcated by the internal elastic lamina, and that between the media and adventitia by the external elastic lamina. The adventitia gradually merges with loose connective tissue around the vessel, often surrounded by a layer of adipose tissue.2,3
|
The Adventitia as a "Launching Pad" for Ameliorative Vasoactive Agents |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Because of the apparent ease of surgical access and the interest in averting endothelial damage, recent studies have used gene transfer to the adventitia as a means of correcting vascular dysfunction. After successful transfection of cerebral vessel adventitial cells was demonstrated by intracerebroventricular injections of adenovirus, a series of landmark studies has shown that the adventitia is a useful platform for expression of tissue-permeant hormones such as nitric oxide (NO).5–8 Their effectiveness in correcting vascular dysfunction is based on the premise that NO is a freely diffusible and stable species that can penetrate the media. The resulting focus on the adventitia raises an important question as to its physiological role as a paracrine mediator of vascular function.
|
Activation of the Adventitia in Vascular Disease |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Hypertension, atherosclerosis, and vascular injury all activate perivascular cells and increase macrophage levels in the perivascular space.9–11 As far back as 1915, Allbutt12 reported finding inflammatory cells in the adventitia of atherosclerotic arteries. In 1962, Schwartz and Mitchell13 demonstrated a positive relationship between the degree of adventitial inflammation and severity of atherosclerosis. Combined with leukocyte infiltration, characteristic fibroblast proliferation will likely increase perivascular production of O2- and impair endothelium-dependent relaxation (EDR). Generation of angiotensin II (AngII) and cytokines by perivascular adipose tissue14 and the interstitium,15 as well as macrophages and mast cells present in the adventitia,11 could also potentiate endogenous O2- production16 and lead to the production of other ROS, including hydrogen peroxide (H2O2), which is cell-permeant and likely to affect vascular smooth muscle responsiveness.17,18 In fact, mast cells do contain a leukocyte-like NADPH oxidase.19 Adventitial NAD(P)H oxidase activity may affect nitrergic neurotransmission, since adventitial fibroblasts are juxtaposed to adventitial nerve endings that produce NO·.20 Therefore, in vivo adventitial O2- may play an even more extensive role in the control of vascular tone than the one observed in vitro.
|
Interactions of Adventitial ROS With EDRF |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Almost immediately after the discovery of EDRF, it was surmised that O2- was involved in its destruction.21,22 It was later discovered that EDRF is NO, a free radical that is essentially inactivated by reaction with O2-.23 Clearly, O2- can interfere with NO-dependent vasodilatation21,24 and participate in endothelium-dependent constriction.25 An inducible phagocyte-like NAD(P)H oxidase has been reported in the endothelium26–29 and smooth muscle30,31 and has been cited in the regulation of NO bioactivity. Several key studies described a functional oxidase in these cells and implicated its contribution to impaired endothelial function.27,32,33 Because these O2- sources are near the site of endothelial NO synthase (eNOS)–derived NO, it is broadly accepted that they interfere with the actions of endothelium-derived NO· (EDNO). Our early studies revealed that a major site of vascular O2- production was derived from adventitial NAD(P)H oxidase.34 Although it was not immediately clear how the adventitia might be involved in the elimination of exogenously applied NO, it was implicated just the same by virtue of its action as a physical barrier.35 Wang et al36 showed that this destruction was caused by adventitial O2- and went on to address the significance of the adventitia for bioactivity of EDNO by demonstrating that it interacts with adventitial O2- to enhance passive aortic tone.37 Moreover, recent reports have shown hormonal induction of medial SMC NO,38 further supporting the interaction between vascular NO and adventitial O2-. It was already well known that superoxide dismutase (SOD) can improve relaxation of blood vessels,21,24 and it was later found that xanthine oxidase plays a role in the development of high blood pressure in spontaneously hypertensive rats.39 Our group and others have inferred that O2- derived from NAD(P)H oxidase inhibits NO-dependent relaxation,37,40 and vascular O2- from this oxidase is now implicated in AngII-induced blood pressure elevation.40
Although it is intuitive that endothelial and medial sources of O2- would be impediments to NO, it has not been so clear whether adventitial O2- can substantially inactivate EDNO. Yet a large source of O2- in the adventitia is relevant to EDNO bioactivity. Beckman and Koppenol41 describe O2- as a major scavenger of NO that can act as a sink and lower its bioactive concentrations over its diffusion radius of 150 to 300 µm.42 This phenomenon is related to the ability of NO to diffuse in a Brownian pattern faster than it reacts with most biological substances, including the heme in guanylate cyclase (diffusion rate of 3300 µm2/s under physiological conditions).42 Relevant to this point, the medial thickness of an adult rat common carotid artery is 
60 µm.43 Thus, NO is expected to travel to the adventitia and be inactivated by any major source of O2- within NO’s diffusion radius before it can maximally activate guanylate cyclase in the media. Our most recent experiments suggest that adventitial O2- interferes with EDNO-induced relaxation of the normal mouse aorta. By compartmentalizing the aortic endothelium from the adventitia by isolated perfusion and suffusion, we were able to demonstrate that AngII-induced impairment of EDR was significantly improved by localized delivery of SOD to the adventitia.44 Based on the premise that O2- has a diffusion radius of a few microns, these studies suggest that adventitial O2- (1) acts as a sink for vascular NO (Figure 1A) and/or (2) constricts the outer vascular medial layers or stimulates vasoconstrictor release from the adventitia and (3) stimulates the release of a paracrine mediator of smooth muscle relaxation impairment (Figure 1B). For instance, ROS activate cyclooxygenase and enhance the vasoconstrictor action of prostaglandin H2.45 They also stimulate vascular smooth muscle cells (VSMCs) to release heat-shock protein 90
and cyclophilins,46 which may activate extracellular signal–regulated kinases (ERK1/2) in an autocrine fashion and mediate SMC contraction.47 Possible paracrine mediators of this impairment include cytokine and growth factor release derived from fibroblasts and mast cells.48,49 In fact, the interaction of mast cells with fibroblasts in cardiovascular disease could become an important area of study, because mast cell mediators stimulate fibroblast growth and collagen synthesis.50 Figure 1 illustrates the possible mechanisms by which ROS may directly or indirectly affect the constrictor tone of vascular smooth muscle. Moreover, evidence demonstrating that leukocytes accumulate in the adventitia in the early stages of cardiovascular disease11,51 suggests a role for leukocytes in vascular dysfunction. Interactions of invading macrophages and fibroblast oxidase is also an area of active interest in our laboratory.
|
|
Role of the Vascular Adventitia in Vascular Remodeling |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Proliferation of fibroblasts modulated by O2-52 and a change in the balance of matrix development by fibroblasts could ultimately lead to changes in SMC and endothelial cell growth and vessel dynamics.53 Indeed, adventitial fibroblasts have been described as "most reactive in the vascular wall" and appear to initiate vascular remodeling in response to injury.54
In hypertension, medial hypertrophy of large arteries is a normal response,55 yet the mechanism mediating this hypertrophy is still unclear. Numerous reports have demonstrated that AngII can induce medial thickening and increase cross-sectional area independently of blood pressure elevation.56–58 Other reports argue that pressure mediates much of this effect.59 In SMC cultures, AngII has clearly been shown to induce hypertrophy,60 which is mediated by activation of NAD(P)H oxidase–derived H2O2; this in turn activates proto-oncogenes, ERK1/2, and transcription factors, leading to the growth response.31,61 However, involvement of neighboring cells in medial hypertrophy has not been reported to our knowledge. Inasmuch as studies support activation of adventitial NAD(P)H oxidase by AngII62 and that Fukai et al63 have reported that AngII increases SOD, it is tempting to speculate that H2O2 resulting from adventitial NAD(P)H oxidase activation affects medial SMCs in a variety of ways, including stimulation of hypertrophy and decreased sensitivity of guanylate cyclase. In fact, our data suggest that adventitial NAD(P)H oxidase produces O2- outside the cell,36 which could plausibly be converted by extracellular SOD to H2O2 (a more stable and cell-permeant stimulator of medial smooth muscle hypertrophy).31,61 A recent report by Liao et al46 showed that oxidative stress in SMCs causes the release of heat-shock protein 90, which can activate ERK1/2 in other cells. This important study strongly supports a paracrine effect of oxidative stress in the vasculature, and if this same mechanism exists in adventitial fibroblasts, it may help explain how fibroblast O2- effects medial hypertrophy. More recently, Wang et al64 showed that AngII stimulates NADPH oxidase–derived ROS in the adventitia and intima concomitant with medial hypertrophy. This stimulation was significantly reduced in mice without gp91phox-containing NAD(P)H oxidase, suggesting a paracrine interaction between the media and adjacent vascular layers. Finally, stimulation of the adventitia has been clearly associated with transmodulation of adventitial fibroblasts into myofibroblasts,54 cells that are known to be constrictive and produce large amounts of extracellular matrix.65,66 Both of these characteristics of the myofibroblast are expected to lead to vascular remodeling.
|
Vascular Adventitia in the Injury Response |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
VSMC migration and proliferation have been implicated in narrowing of the arterial lumen in response to injury and atherosclerosis. Although the mechanisms involved are not fully understood, AngII, growth factors, and proto-oncogenes have been suggested. Angiotensin-converting enzyme inhibitors (ACEIs) can prevent neointima formation in response to balloon injury,67,68 and AngII receptor antagonists may also inhibit neointima formation.68 These data suggest that AngII is involved in the process leading to neointimal thickening by way of increased SMC proliferation.69 There is little doubt that SMCs proliferate and migrate to the neointima. However, because AngII induces hypertrophy but not proliferation of VSMCs in culture,31,70 it is not so clear whether AngII induces migration of SMCs to the neointima. Recently, the adventitia has been shown to play an important role in the remodeling response to injury under normotensive conditions. It has been postulated that fibroblast proliferation precedes modulation to myofibroblasts, which then migrate to the neointima.54 Inasmuch as fibroblast proliferation is O2- dependent,52 therapies aimed at targeting O2- production in adventitial fibroblasts may prove useful in treating both the vascular injury response and atherosclerosis. Although the inherent differences among various vascular beds and models of vascular injury are obvious, there is increasing evidence that the adventitia plays a significant role. For example, Patel et al71 have shown that SMCs are more or less differentiated, depending on the vascular bed. This may explain why in coronary arteries, where they are more differentiated, SMCs do not proliferate and migrate. Also, in a porcine model of coronary artery balloon injury used by Shi et al,72 dissection was produced by varying degrees of medial injury, and intima-bound myofibroblasts were found to migrate along medial fissures. However, dissection of the media is not necessary, because direct adventitial injury can cause neointimal lesions even in the absence of endothelial denudation.71,73 Furthermore, Shi et al74 recently showed that in carotid artery-vein grafts, neointimal proliferation is preceded by activation and proliferation of adventitial fibroblasts, modulation to myofibroblasts, and migration to the neointima. Indeed, Holifield et al75 have described carotid adventitial fibroblasts as far more likely to proliferate than carotid SMCs, and Li et al76 showed that in the rat carotid injury model, exogenously modified and seeded carotid adventitial fibroblasts migrate in response to a factor released by SMCs.
However, there remains significant controversy over the relative contribution of medial SMCs and adventitial fibroblasts in neointimal growth. The increased presence of p22phox in dedifferentiated smooth muscle in the vein graft neointima,77 as well as the upregulation of vascular smooth muscle nox1 during restenosis,78 clearly support a role for medial SMCs in this process, as suggested by early studies.79,80 Moreover, in contrast to the studies by Li et al,76 a recent report by de Leon et al81 suggests that resident fibroblasts do not migrate from the adventitia in the rat carotid artery injury model. The differences in the contribution of adventitial nonmuscle cells in various vascular beds are likely to be traced to the arteries being studied and the degree of injury sustained. With regard to the former, the developmental origin of SMCs and fibroblasts is likely to ascribe a different proliferative and migratory phenotype to SMCs, depending on their origin.71 Regardless of the origin of the neointimal cells, there appears to be little doubt that the adventitia plays an important role (whether direct or indirect) in neointima development in these models. Perhaps indirect influences include adventitial release of transforming growth factor-ß in response to an increase in ROS levels, which causes cell proliferation.82 Our recent studies targeting NAD(P)H oxidase in adventitial cells with adenoviral vectors expressing oxidase inhibitor have revealed substantial reductions in O2- and neointimal growth, suggesting interaction between adventitial oxidase and vascular cell proliferation and migration.83 Cross-talk between the vascular segments is currently a focus of intense interest in our laboratory.
|
Role of the Adventitia in Atherosclerosis |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
A variety of studies have suggested that the adventitia is activated during the development of atherosclerosis.13,84,85 AngII is known to induce ROS formation in vitro and in vivo, and oxidative stress plays a role in hypercholesterolemia, atherosclerosis, and vascular injury.86,87 The renin-angiotensin system has been implicated in the progression of atherosclerosis in animal models,86,88–90 and recent clinical evidence from the Heart Outcomes Prevention Evaluation trial has shown reduced overall cardiac morbidity and mortality in normotensive patients at higher risk for cardiovascular disease who were treated with an ACEI.91 Although the mechanisms involved are not yet clear, there is abundant evidence that the cellular actions of AngII are pro-inflammatory and potentially injurious to the blood vessel. Reports have shown that ACEIs and AT1 antagonists are capable of lessening lesion formation in atherosclerosis.92 Others have shown NAD(P)H oxidase activation in hypercholesterolemia and atherosclerosis.93–95 More recently, Daugherty et al51 showed that subpressor doses of AngII could promote lesion formation and aneurysm formation in apo E -/- mice; however, the mechanisms involved were not described. Adventitial proliferation was activated in those aortic regions where aneurysms were present. Thus, it is tempting to speculate that activation of adventitial oxidase may be an early signaling agent in this response. Two recent reports showed that a deficiency in an essential component of the leukocyte-related NAD(P)H oxidase had no effect on atherosclerotic lesion formation in apo E -/- mice under nonhypertensive conditions.96,97 However, one more recent study indicated that p47phox deletion diminished progression of atherosclerosis in apo E -/- mice in areas of the mouse aorta with lower degrees of lesion formation.98 Thus, studies are required to carefully examine the upregulation of oxidase isoforms during the development of atherosclerosis from early to late stages. We also believe that AngII, acting by way of stimulation of NAD(P)H oxidase, may be necessary before the oxidase can be fully involved in atherosclerosis, and thus, models that exhibit renin-angiotensin system activation should be considered. Such studies may provide the elusive link between hypertension and an increased propensity for atherosclerosis and clarify whether adventitial cells and their oxidases are involved directly or indirectly in lesion development.
|
Prototype NADPH Oxidase in the Phagocyte |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Phagocyte NADPH oxidase (or respiratory burst oxidase) is a well-characterized ROS-generating system that catalyzes the one-electron reduction of oxygen to O2-. It is a multicomponent enzyme complex that includes the 2 membrane-spanning polypeptide subunits p22phox and gp91phox that are associated with the membrane cytoskeleton (which together comprise flavocytochrome b558) and 4 cytoplasmic polypeptide subunits, p47phox, p67phox,99,100 p40phox,101 and the cytosolic guanine nucleotide–binding protein p21rac, a member of the Ras family of peptides.102 Exposure of the cell to a variety of agonists induces phosphorylation of cytosolic components and association of cytosolic and membrane-associated components and activates normally dormant oxidase.99
|
NAD(P)H Oxidases in VSMCs, Endothelial Cells, and Adventitial Fibroblasts |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Numerous reports have demonstrated NAD(P)H oxidase(s) in VSMCs,31,103 endothelial cells,26 and fibroblasts.104,105 Before these more recent discoveries, the most widely studied sources of O2- were NAD(P)H oxidase in white cells106 and xanthine oxidase in endothelial cells,107 which plays an important role in impaired EDR of aortas from hypercholesterolemic rabbits. Ushio-Fukai et al108 extensively described an NAD(P)H oxidase that interferes with relaxation in VSMCs of the rat aorta, which express the mRNA for 1 of the cytochrome b558 subunits found in phagocyte membranes, p22phox. They also found a homologue of gp91phox, called nox1, in smooth muscle that participates in O2- production and serum-dependent growth.4 In cultured rat aortic SMCs, NAD(P)H oxidase O2- activity is stimulated by AngII and is involved in the hypertrophic response108 as well as in the development of hypertension.32 Using the clone for p22phox, Fukui et al109 showed by in situ hybridization that this important NAD(P)H oxidase component is also present in the adventitia. Endothelial cells of the bovine pulmonary artery103 as well as the human umbilical vein26,110 have been shown to contain an O2--generating NADH oxidase and all 4 major neutrophil-like components, including gp91phox. Bayraktutan et al28 showed that endothelial gp91phoxand p22phox are homologous with the corresponding components in the human neutrophil. We partially cloned p67phox and found a very high degree of homology with human neutrophil p67phox and reported its potent transcriptional induction by AngII;62 recent partial cloning of gp91phox in rabbit adventitial fibroblasts showed that it is highly homologous to the human neutrophil gp91phox,111 suggesting a marked similarity between fibroblast and endothelial oxidase isoforms.
|
Structural Differences in NAD(P)H Oxidases Present in VSMCs Versus Fibroblasts |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Early studies of phagocyte NAD(P)H oxidase formed the basis of comparison for vascular isozymes. Preliminary evidence suggests that the fibroblast enzyme resembles the phagocytic enzyme,112 whereas the VSMC oxidase varies significantly in its gp91phox homologues. VSMCs and fibroblasts have NAD(P)H oxidases that both appear to be associated with the plasma membrane. Whereas fibroblast expression of gp91phox (nox2) has been reported in many species,36,105,113 much of the evidence suggests it is weakly expressed at the protein level in VSMCs; moreover, very low levels of mRNA were detected in rat aortic VSMCs, the focus of most studies.114 In contrast, expression of gp91phox homologues nox1 (mitogenic oxidase) and nox4 has been detected78; human nox1 exhibits 56% homology with prototype human gp91phox, and nox4 has 37% homology. The major functional domains are conserved among the homologues.115 In contrast, in the fibroblast, we have screened a cDNA library prepared from rabbit fibroblasts and obtained an 843-nucleotide bp coding region of neutrophil gp91phox (amino acids 251 to 532 of neutrophil gp91phox) identical in sequence to the rabbit fibroblast sequence.111 p22phox has been found in both cellular types and has been described as functionally required by the enzyme in aortic VSMCs.105,108 In rat VSMCs, p22phox cDNA bears a high homology to the human neutrophil nucleotide sequence.116
Cytosolic p47phox is reportedly present in VSMCs117 and fibroblasts,36 and there is evidence that it is an essential component in VSMCs,118 although it is not yet clear whether this subunit binds nox1 or nox4. The other major cytosolic component of phagocyte NAD(P)H oxidase, p67phox, has been detected in fibroblasts62,105,119; a 714-bp aortic fibroblast cDNA sequence shares 94.6% homology with the human phagocyte p67phox.62 The presence of p67phox appears necessary for maximal activation of the oxidase in fibroblasts.62 However, this subunit has not yet been found in VSMCs, even at the messenger level.117 Small GTP-binding proteins were also described in the vascular oxidases: Rac2 was found in membranes of thrombin-stimulated human aortic VSMCs,117 and transfection of NIH 3T3 fibroblasts with a dominant-negative allele of Rac1 decreased ROS production.52
|
Activation and Kinetics |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
These structural differences between oxidases likely lead to differences in biochemical behavior as well as enzymatic activity. Phagocyte NAD(P)H oxidase does not produce O2- under basal conditions; however, VSMCs and fibroblasts exhibit low basal O2- activity.105 Early data indicated that vascular oxidase (unlike neutrophil oxidase) is assembled and constitutively active under normal conditions.31,34,105 More recently, upregulation of p22phox, p47phox, p67phox, and gp91phox and its homologues113 has suggested that active assembly is occurring during hormonal stimulation.117
Other stimuli of NAD(P)H oxidase include thrombin, a potent VSMC mitogen. Thrombin increases intracellular ROS concomitant with p47phox, and Rac2 translocation to the membrane also upregulates p47phox expression at the mRNA and protein level.117 Tumor necrosis factor- produces a sustained increase in NAD(P)H oxidase activity in human skin fibroblasts16 and aortic VSMCs.120 Interleukin-1 and transforming growth factor-ß, a potent fibrogenic agent overexpressed in vascular restenosis, effectively activate NAD(P)H oxidase in human fibroblasts.16,121 Whereas these vascular cells seem to exhibit similar kinetics, differences have been observed in the amounts of O2- released under basal and stimulated conditions. Homogenates of aortic fibroblasts have higher NADH- and NADPH-dependent oxidase activity than do aortic SMCs under vehicle or AngII treatment76; moreover, we reported the adventitia as a major source of O2- in the rabbit and rat aorta.36,105 Similar results were obtained by Shi et al,9 who measured O2- production in coronary arteries; ie, fibroblasts from uninjured vessels produced significantly higher levels of O2- than did coronary SMCs.
|
Evidence for the Involvement of Vascular NAD(P)H Oxidase–Derived ROS in Cell Signaling Leading to Cellular Growth |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
The interaction of ROS at the whole-cell level appears to take place at growth factor receptors. Epidermal growth factor receptor (EGF-R) and platelet-derived growth factor receptor are both transactivated by AngII, a process mediated by ROS derived from NAD(P)H oxidases.122 The resulting tyrosine phosphorylation generally leads to activation of src homology complex–growth factor receptor–bound protein 2–son of sevenless complex (Shc-Grb2-Sos) that activates ras, leading to downstream activation of mitogen-activated protein kinases (MAPKs) and transcription factors. Some of the key redox-sensitive kinases playing a role in this cascade are ERK1/2, c-Jun N-terminal kinases, big MAPK, and p38 MAPK,123–125 which appear to converge at the site of activation of the Akt/protein kinase B pathway and result in cellular hypertrophy.126,127 NAD(P)H oxidases have been most clearly implicated in the activation of p38 MAPK and JNK.123,128 In response to oxidative stress, VSMCs also secrete factors that promote ERK1/2 activation and growth.46,129 Cyclophilin A (CyPA) is an important oxidative stress–induced factor, which is secreted by VSMCs and fibroblasts during oxidative stress,129 and injured coronary arteries secrete CyPA during the first week after injury, concomitant with neointimal proliferation (for a comprehensive review on signaling, see Griendling et al126).
|
Does Divergent Signaling in Fibroblasts Lead to Cell Proliferation? |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
Whereas ROS stimulate MAPK activation, gene transcription, and primarily hypertrophy in VSMCs,61,126,130 in fibroblasts a mitogenic response appears to prevail. In vascular adventitial fibroblasts per se, the involvement of specific redox-sensitive signaling pathways leading to cell proliferation is less clear. However, a few key studies provide insight into these mechanisms, and we are able to glean important information from a variety of other fibroblast preparations. EGF-R internalization, ubiquitination, and thus, downregulation are inhibited by H2O2 in human 3T3 fibroblasts.131 Irani et al52 showed that p21ras-transformed NIH 3T3 fibroblasts could produce increased amounts of ROS, apparently through the activation of rac1 and NAD(P)H oxidase; they also demonstrated ERK1/2 activation by Raf, a downstream effector of p21ras. AngII is known to activate p21ras, but to our knowledge, this has not been confirmed in fibroblasts. In embryonic fibroblasts, ROS activate Fyn, which phosphorylates JAK2, and this in turn activates Ras and Raf,132 which are both implicated in cell cycle progression and fibroblast mitogenesis.52 Although ROS are suggested to be involved in transmodulation of fibroblasts to myofibroblasts, the pathways involved in this process are not known (Figure 2). Cytokine-induced c-myc gene expression in human dermal fibroblasts is mediated by the redox-sensitive nuclear factor-
B,133 which may explain how adventitial inflammation can activate fibroblast proliferation. Still, there appears to be a high degree of overlap in the signal-transducing pathways of VSMCs and fibroblasts, which ultimately promote hypertrophy and mitogenesis, respectively. Thus, VSMCs and fibroblasts likely vary widely in their ability to activate cell cycle arrest inhibitors such as p27Kip, which is induced by AngII and activated by ROS.134 One very enlightening study examining the ability of NO to increase p21Sdi1/Cip1/Waf1 kinase inhibitor levels shows clear divergence in the pathways leading to S-phase arrest.135
|
Currently, the major apparent differences between fibroblasts and VSMCs are at the level of nox isoforms, perhaps suggesting a link between the isoform, its subcellular distribution, and function. In fact, it has been predicted that nox4 is confined to the endoplasmic reticulum and is involved in cell quiescence,114 suggesting that its unique expression in VSMCs (versus other nox isoforms in fibroblasts) could predispose VSMCs to pathways leading to cell cycle inhibition, including p27Kip and Akt/protein kinase B expression. Because upstream signaling agents converging at the various MAPKs appear to be markedly similar, there is likely a unique combination of transcription factors and early-response genes that allows fibroblasts to enter the cell cycle and proliferate, whereas VSMCs do not. Inasmuch as p53 tumor suppressor protein has recently been demonstrated to differentiate senescent cells from quiescent cells and appears to be irreversible in senescent cells,136 one question that remains to be addressed is whether p53 is induced by ROS and more tightly coupled and irreversible in VSMCs. It is also likely that the various nox isoforms vary significantly in their ROS-producing capacities. Thus, the sensitivities of colocalized kinases to ROS derived from these isoforms will likely be critical in whether or not a particular pathway is activated.
|
Conclusions |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
The adventitia is increasingly being considered a highly active segment of vascular tissue that contributes to a variety of disease pathologies, including atherosclerosis and hypertension. Sensitivity of adventitial fibroblasts to local stimuli involved in the production of NAD(P)H oxidase–derived ROS could affect the function of the entire vascular wall, including endothelial dysfunction and the ability of vascular cells to proliferate. Many questions remain as to the specific pathways initiated by NAD(P)H oxidase, which diverge in adventitial cells and VSMCs, leading to either hyperplasia or hypertrophy.
|
Acknowledgments |
|---|
This work was supported by NIH NHLBI grants HL55425 and HL28982 and by American Heart Association grants 95011900 and 9808086W.
Received July 26, 2002; accepted September 30, 2002.
|
References |
|---|
|
TopAbstractIntroductionAnatomy of a Blood...The Adventitia as a...Activation of the Adventitia...Interactions of Adventitial ROS...Role of the Vascular...Vascular Adventitia in the...Role of the Adventitia...Prototype NADPH Oxidase in...NAD(P)H Oxidases in VSMCs,...Structural Differences in...Activation and KineticsEvidence for the Involvement...Does Divergent Signaling in...ConclusionsReferences |
|---|
1. Stedman TL. Stedman’s Medical Dictionary. Baltimore: Williams & Wilkins; 1995.
2. Fawcett DW. Blood and lymph vascular systems. In: Bloom and Fawcett Textbook of Histology. New York: Chapman & Hall; 1994: 368–409.
3. Kelly DE, Wood RL, Enders AC. The circulatory systems. In: Bailey’s Textbook of Microscopic Anatomy. Baltimore: Williams & Wilkins; 1984: 387–424.
4. Suh Y-A, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 1999; 401: 79–82.Letter.[CrossRef][Medline] [Order article via Infotrieve]
5. O’Brien T. Adenoviral vectors and gene transfer to the blood vessel wall. Arterioscler Thromb Vasc Biol. 2000; 20: 1414–1416.
6. Kullo IJ, Simari RD, Schwartz RS. Vascular gene transfer: from bench to bedside. Arterioscler Thromb Vasc Biol. 1999; 19: 196–207.
7. Ríos CD, Ooboshi H, Piegors D, Davidson BL, Heistad DD. Adenovirus-mediated gene transfer to normal and atherosclerotic arteries: a novel approach. Arterioscler Thromb Vasc Biol. 1995; 15: 2241–2245.
8. Chen AFY, Jiang S-W, Crotty TB, Tsutsui M, Smith LA, O’Brien T, Katusic ZS. Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proc Natl Acad Sci U S A. 1997; 94: 12568–12573.
9. Shi Y, Niculescu R, Wang D, Patel S, Davenpeck KL, Zalewski A. Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler Thromb Vasc Biol. 2001; 21: 739–745.
10. Tamura K, Kanzaki T, Tashiro J, Yokote K, Mori S, Ueda S, Saito Y, Morisaki N. Increased atherogenesis in Otsuka Long-Evans Tokushima fatty rats before the onset of diabetes mellitus: association with overexpression of PDGF ß-receptors in aortic smooth muscle cells. Atherosclerosis. 2000; 149: 351–358.[CrossRef][Medline] [Order article via Infotrieve]
11. Capers Q IV, Alexander RW, Lou P, de Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997; 30: 1397–1402.
12. Allbutt C. Diseases of the Arteries Including Angina Pectoris. London: Macmillan and Co: 1915.
13. Schwartz CJ, Mitchell JRA. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation. 1962; 26: 73–78.
14. Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res. 1988; 62: 1259–1262.
15. Guan S, Fox J, Mitchell KD, Navar LG. Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension. 1992; 20: 763–767.
16. Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-. Biochem J. 1989; 263: 539–545.[Medline]
[Order article via Infotrieve]
17. Milligan SA, Owens MW, Grisham MB. Differential regulation of extracellular signal-regulated kinase and nuclear factor-B signal transduction pathways by hydrogen peroxide and tumor necrosis factor. Arch Biochem Biophys. 1998; 352: 255–262.[CrossRef][Medline]
[Order article via Infotrieve]
18. Torrecillas G, Boyano-Adánez MdC, Medina J, Parra T, Griera M, López-Ongil S, Arilla E, Rodríguez-Puyol M, Rodríguez-Puyol D. The role of hydrogen peroxide in the contractile response to angiotensin II. Mol Pharmacol. 2000; 59: 104–112.
19. Fukuishi N, Sakaguchi M, Matsuura S, Nakagawa C, Akagi R, Akagi M. The mechanisms of compound 48/80-induced superoxide generation mediated by A-kinase in rat peritoneal mast cells. Biochem Mol Med. 1997; 61: 107–113.[CrossRef][Medline] [Order article via Infotrieve]
20. Paisley K, Martin W. Blockade of nitrergic transmission by hydroquinone, hydroxocobalamin and carboxy-PTIO in bovine retractor penis: role of superoxide anion. Br J Pharmacol. 1996; 117: 1633–1638.[Medline] [Order article via Infotrieve]
21. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986; 320: 454–456.Letter.[CrossRef][Medline] [Order article via Infotrieve]
22. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986; 250: H822–H827.[Medline] [Order article via Infotrieve]
23. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990; 87: 1620–1624.
24. Mugge A, Elwell JH, Peterson TE, Harrison DG. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 1991; 260: C219–C225.[Medline] [Order article via Infotrieve]
25. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol. 1989; 257: H33–H37.[Medline] [Order article via Infotrieve]
26. Jones SA, O’Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OTG. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol. 1996; 271: H1626–H1634.[Medline] [Order article via Infotrieve]
27. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000; 87: 26–32.
28. Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20: 1903–1911.
29. Mohazzab-H KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 1994; 266: H2568–H2572.[Medline] [Order article via Infotrieve]
30. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002: 90: 1205–1213.
31. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74: 1141–1148.
32. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997; 95: 588–593.
33. Mollnau H, Wendt M, Szöcs K, Lassègue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Förstermann U, Meinertz T, Griendling K, Münzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002; 90: e58–e65.
34. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol. 1995; 268: H2274–H2280.[Medline] [Order article via Infotrieve]
35. Steinhorn RH, Morin IFC, Russell JA. The adventitia may be a barrier specific to nitric oxide in rabbit pulmonary artery. J Clin Invest. 1994; 94: 1883–1888.[Medline] [Order article via Infotrieve]
36. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, Cohen RA. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res. 1998; 82: 810–818.
37. Wang HD, Hope S, Du Y, Quinn MT, Cayatte A, Pagano PJ, Cohen RA. Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension. Hypertension. 1999; 33: 1225–1232.
38. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996; 137: 1798–1803.[Abstract]
39. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A. 1991; 88: 10045–10048.
40. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996; 97: 1916–1923.[Medline] [Order article via Infotrieve]
41. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 1996; 271: C1424–C1437.[Medline] [Order article via Infotrieve]
42. Lancaster JR Jr. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide. 1997; 1: 18–30.[CrossRef][Medline] [Order article via Infotrieve]
43. Jacobson GM, Carretero OA, Pagano PJ. A cell-permeant NAD(P)H oxidase inhibitor reduces balloon injury-induced neointimal proliferation in the rat carotid artery. Hypertension. 2001; 38: 472. Abstract.
44. Rey FE, Li X-C, Carretero OA, Garvin JL, Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91phox. Circulation. 2002; 106: 2497–2502.
45. Pomposiello S, Yang X-P, Liu Y-H, Surakanti M, Rhaleb N-E, Sevilla M, Carretero OA. Autacoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition. J Cardiovasc Pharmacol. 1997; 30: 599–606.[CrossRef][Medline] [Order article via Infotrieve]
46. Liao D-F, Jin Z-G, Baas AS, Daum G, Gygi SP, Aebersold R, Berk BC. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem. 2000; 275: 189–196.
47. Touyz RM, El Mabrouk M, He G, Wu X-H, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ Res. 1999; 84: 505–515.
48. Delehedde M, Seve M, Sergeant N, Wartelle I, Lyon M, Rudland PS, Fernig DG. Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. J Biol Chem. 2000; 275: 33905–33910.
49. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001: 158: 1111–1120.
50. Panizo A, Pardo Mindán FJ, Galindo MF, Cenarruzabeitia E, Hernández M, Díez J. Are mast cells involved in hypertensive heart disease? J Hypertens. 1995; 13: 1201–1208.[Medline] [Order article via Infotrieve]
51. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000; 105: 1605–1612.[Medline] [Order article via Infotrieve]
52. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997; 275: 1649–1652.
53. Chatelain RE, Dardik B. Increased DNA replication in the arterial adventitia after aortic ligation. Hypertension. 1988; 11: I-130–I-134.[Medline] [Order article via Infotrieve]
54. Zalewski A, Shi Y. Vascular myofibroblasts: lessons from coronary repair and remodeling. Arterioscler Thromb Vasc Biol. 1997; 17: 417–422.
55. Owens GK, Rabinovitch PS, Schwartz SM. Smooth muscle cell hypertrophy versus hyperplasia in hypertension. Proc Natl Acad Sci U S A. 1981; 78: 7759–7763.
56. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991; 17: 626–635.
57. Schiffers PMH, van der Heijden HAMD, Fazzi GE, Struijker Boudier HAJ, De Mey JGR. Tonic tone in arteries exposed continuously to angiotensin II in vitro. J Pharmacol Exp Ther. 1993; 266: 1520–1527.
58. Plunkett WC, Overbeck HW. Increased arteriolar wall-to-lumen ratio in a normotensive vascular bed in coarctation hypertension. Am J Physiol. 1985; 249: H859–H866.[Medline] [Order article via Infotrieve]
59. Parker SB, Wade SS, Prewitt RL. Pressure mediates angiotensin II-induced arterial hypertrophy and PDGF-A expression. Hypertension. 1998; 32: 452–458.
60. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989; 13: 305–314.
61. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992; 70: 593–599.
62. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension. 1998; 32: 331–337.
63. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res. 1999; 85: 23–28.
64. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001; 88: 947–953.
65. Sappino AP, Schürch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 1990; 63: 144–161.[Medline] [Order article via Infotrieve]
66. Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol. 1997; 29: 31–42.[CrossRef][Medline] [Order article via Infotrieve]
67. Powell JS, Clozel J-P, Müller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989; 245: 186–188.
68. Farhy RD, Carretero OA, Ho K-L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res. 1993; 72: 1202–1210.
69. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991; 18 (suppl II): II-100–II-105.[Medline] [Order article via Infotrieve]
70. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988; 62: 749–756.
71. Patel S, Shi Y, Niculescu R, Chung EH, Martin JL, Zalewski A. Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation. 2000; 101: 524–532.
72. Shi Y, Pieniek M, Fard A, O’Brien J, Mannion JD, Zalewski A. Adventitial remodeling after coronary arterial injury. Circulation. 1996; 93: 340–348.
73. Barker SGE, Talbert A, Cottam S, Baskerville PA, Martin JF. Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb. 1993; 13: 70–77.
74. Shi Y, O’Brien JE Jr, Mannion JD, Morrison RC, Chung W, Fard A, Zalewski A. Remodeling of autologous saphenous vein grafts: the role of perivascular myofibroblasts. Circulation. 1997; 95: 2684–2693.
75. Holifield B, Helgason T, Jemelka S, Taylor A, Navran S, Allen J, Seidel C. Differentiated vascular myocytes: are they involved in neointimal formation? J Clin Invest. 1996; 97: 814–825.[Medline] [Order article via Infotrieve]
76. Li G, Chen Y-F, Greene GL, Oparil S, Thompson JA. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation. 1999; 100: 1639–1645.
77. West NEJ, Guzik TJ, Black E, Channon KM. Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2001; 21: 189–194.
78. Szöcs K, Lassègue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002; 22: 21–27.
79. Ross R. Atherosclerosis: a defense mechanism gone awry (Rous-Whipple Award Lecture). Am J Pathol. 1993; 143: 987–1002.[Medline] [Order article via Infotrieve]
80. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res. 1986; 58: 427–444.
81. de Leon H, Ollerenshaw JD, Griendling KK, Wilcox JN. Adventitial cells do not contribute to neointimal mass after balloon angioplasty of the rat common carotid artery. Circulation. 2001; 104: 1591–1593.
82. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-ß1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995; 27: 2347–2357.[CrossRef][Medline] [Order article via Infotrieve]
83. Dourron HM, Jacobson GM, Reddy DJ, Pagano PJ. Adventitial gene transfer of NAD(P)H oxidase inhibitor suppresses increased superoxide following balloon angioplasty in the rat carotid artery. Hypertension. 2002; 40: 383. Abstract.
84. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol. 1996; 54 (suppl): S21–S35.[CrossRef][Medline] [Order article via Infotrieve]
85. van der Loo B, Martin JF. The adventitia, endothelium and atherosclerosis. Int J Microcirc. 1997; 17: 280–288.[Medline] [Order article via Infotrieve]
86. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997; 96: 3264–3265.[Medline] [Order article via Infotrieve]
87. Berk BC, Haendeler J, Sottile J. Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest. 2000; 105: 1525–1526.[Medline] [Order article via Infotrieve]
88. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999; 12: 28–34.[Medline] [Order article via Infotrieve]
89. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992; 20: 473–477.
90. Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol. 1990; 13: VII-43–VII-48.[Medline] [Order article via Infotrieve]
91. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253–259.[CrossRef][Medline] [Order article via Infotrieve]
92. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in Apo E-deficient mice. Circulation. 2001; 103: 448–454.
93. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998; 82: 1298–1305.
94. Shriver AE, Li W, Weintraub NL, Miller FJ. Superoxide levels and NADPH oxidase activity are increased in neointimal as compared with medial smooth muscle cells. J Invest Med. 2000; 48: 248A. Abstract.
95. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999; 100: 1494–1498.
96. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000; 20: 1529–1535.
97. Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T. Vascular effects following homozygous disruption of p47phox: an essential component of NADPH oxidase. Circulation. 2000; 101: 1234–1236.
98. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ETH, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE-/- mice. J Clin Invest. 2001; 108: 1513–1522.[CrossRef][Medline] [Order article via Infotrieve]
99. DeLeo FR, Quinn MT. Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leukoc Biol. 1996; 60: 677–691.[Abstract]
100. Zhan S, Vazquez N, Zhan SH, Wientjes FB, Budarf ML, Schrock E, Ried T, Green ED, Chanock SJ. Genomic structure, chromosomal localization, start of transcription, and tissue expression of the human p40-phox, a new component of the nicotinamide adenine dinucleotide phosphate-oxidase complex. Blood. 1996; 88: 2714–2721.
101. Cross AR. p40phox participates in the activation of NADPH oxidase by increasing the affinity of p47phox for flavocytochrome b558. Biochem J. 2000; 349: 113–117.[CrossRef][Medline] [Order article via Infotrieve]
102. Knaus UG, Morris S, Dong H-J, Chernoff J, Bokoch GM. Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. Science. 1995; 269: 221–223.
103. Mohazzab-H KM, Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am J Physiol. 1994; 267: L815–L822.[Medline] [Order article via Infotrieve]
104. Meier B, Cross AR, Hancock JT, Kaup FJ, Jones OTG. Identification of a superoxide-generating NADPH oxidase system in human fibroblasts. Biochem J. 1991; 275: 241–245.[Medline] [Order article via Infotrieve]
105. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A. 1997; 94: 14483–14488.
106. Heyworth PG, Peveri P, Curnutte JT. Biological oxidant: generation and injurious consequences. In: Cochrane CC, Gimbrone MA Jr, eds. Cell and Molecular Mechanics of Inflammation. San Diego: Academic Press; 1992.
107. Arroyo CM, Carmichael AJ, Bouscarel B, Liang JH, Weglicki WB. Endothelial cells as a source of oxygen-free radicals: an ESR study. Free Radic Res Commun. 1990; 9: 287–296.[Medline] [Order article via Infotrieve]
108. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996; 271: 23317–23321.
109. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q IV, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997; 80: 45–51.
110. Meyer JW, Holland JA, Ziegler LM, Chang M-M, Beebe G, Schmitt ME. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells: a potential atherogenic source of reactive oxygen species. Endothelium. 1999; 7: 11–22.[Medline] [Order article via Infotrieve]
111. Pagano PJ. Vascular gp91phox: beyond the endothelium. Circ Res. 2000; 87: 1–3.
112. Chamseddine AH, Miller FJ. Gp91phox is necessary for production of superoxide by NADPH oxidase in vascular fibroblasts but not smooth muscle cells. J Invest Med. 2000; 48: 247A. Abstract.
113. Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. Upregulation of p67phox and gp91phox in aortas from angiotensin II-infused mice. Am J Physiol. 2000; 279: H2234–H2240.
114. Lassègue B, Sorescu D, Szöcs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91phox homologues in vascular smooth muscle cells. nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001; 88: 888–894.
115. Cheng G, Cao Z, Xu X, Van Meir EG, Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 2001; 269: 131–140.[CrossRef][Medline] [Order article via Infotrieve]
116. Fukui T, Lassegue B, Kai H, Alexander RW, Griendling KK. Cytochrome b-558 -subunit cloning and expression in rat aortic smooth muscle cells. Biochim Biophys Acta. 1995; 1231: 215–219.[Medline]
[Order article via Infotrieve]
117. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999; 274: 19814–19822.
118. Lavigne MC, Malech HL, Holland SM, Leto TL. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation. 2001; 104: 79–84.
119. Meier B, Jesaitis AJ, Emmendorffer A, Roesler J, Quinn MT. The cytochrome b-558 molecules involved in the fibroblast and polymorphonuclear leucocyte superoxide-generating NADPH oxidase systems are structurally and genetically distinct. Biochem J. 1993; 289: 481–486.[Medline] [Order article via Infotrieve]
120. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J. 1998; 329: 653–657.[Medline]
[Order article via Infotrieve]
121. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor ß1. J Biol Chem. 1995; 270: 30334–30338.
122. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski H, Halleran S, Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001; 21: 489–495.
123. Laderoute KR, Webster KA. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res. 1997; 80: 336–344.
124. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J Biol Chem.;. 2000; 275: 11706–11712.
125. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee J-D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem. 1996; 271: 16586–16590.
126. Griendling KK, Sorescu D, Lassègue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000; 20: 2175–2183.
127. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998; 273: 15022–15029.
128. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kübler W, Kreuzer J. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol. 2000; 20: 940–948.
129. Jin Z-G, Melaragno MG, Liao D-F, Yan C, Haendeler J, Suh Y-A, Lambeth JD, Berk BC. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000; 87: 789–796.
130. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2- in vascular smooth muscle cells. Circ Res. 1995; 77: 29–36.
131. de Wit R, Capello A, Boonstra J, Verkleu AJ, Post JA. Hydrogen peroxide inhibits epidermal growth factor receptor internalization in human fibroblasts. Free Radic Biol Med. 2000; 28: 28–38.[CrossRef][Medline] [Order article via Infotrieve]
132. Abe J, Berk BC. Fyn and JAK2 mediate Ras activation by reactive oxygen species. J Biol Chem. 1999; 274: 21003–21010.
133. Kessler DJ, Duyao MP, Spicer DB, Sonenshein GE. NF-kB-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts. J Exp Med. 1992; 176: 787–792.
134. Hannken T, Schroeder R, Stahl RAK, Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int. 1998; 54: 1923–1933.[CrossRef][Medline] [Order article via Infotrieve]
135. Gu M, Brecher P. Nitric oxide-induced increase in p21Sdi1/Cip1/Waf1 expression during the cell cycle in aortic adventitial fibroblasts. Arterioscler Thromb Vasc Biol. 2000; 20: 27–34.
136. Itahana K, Dimri GP, Hara E, Itahana Y, Zou Y, Desprez P-Y, Campisi J. A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem. 2002; 277: 18206–18214.
This article has been cited by other articles:
 |
|
 |
|
  R. M. Wadsworth Oxidative stress and the endothelium Exp Physiol, January 1, 2008; 93(1): 155 - 157. [Full Text] [PDF]
|
|
|
|
 |
|
 R. C.M. Siow and A. T. Churchman Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in Cardiovasc Res, September 1, 2007; 75(4): 659 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Auger, P. D'Orleans-Juste, and L. Germain Adventitia contribution to vascular contraction: Hints provided by tissue-engineered substitutes Cardiovasc Res, September 1, 2007; 75(4): 669 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Haurani and P. J. Pagano Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease? Cardiovasc Res, September 1, 2007; 75(4): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gavazzi, C. Deffert, C. Trocme, M. Schappi, F. R. Herrmann, and K.-H. Krause NOX1 Deficiency Protects From Aortic Dissection in Response to Angiotensin II Hypertension, July 1, 2007; 50(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Calciotropic Hormones and Arterial Physiology: "D"-lightful Insights J. Am. Soc. Nephrol., February 1, 2007; 18(2): 369 - 373. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Szasz, K. Thakali, G. D. Fink, and S. W. Watts A Comparison of Arteries and Veins in Oxidative Stress: Producers, Destroyers, Function, and Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 27 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamaji-Kegan, Q. Su, D. J. Angelini, H. C. Champion, and R. A. Johns Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2 Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1159 - L1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Stenmark, K. A. Fagan, and M. G. Frid Hypoxia-Induced Pulmonary Vascular Remodeling: Cellular and Molecular Mechanisms Circ. Res., September 29, 2006; 99(7): 675 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Mallawaarachchi, P. L. Weissberg, and R. C. M. Siow Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs? FASEB J, August 1, 2006; 20(10): 1686 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Pagano and M. J. Haurani Vascular Cell Locomotion: Osteopontin, NADPH Oxidase, and Matrix Metalloproteinase-9 Circ. Res., June 23, 2006; 98(12): 1453 - 1455. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weaver, J. Liu, D. Pimentel, D. J. Reddy, P. Harding, E. L. Peterson, and P. J. Pagano Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1933 - H1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Stenmark, N. Davie, M. Frid, E. Gerasimovskaya, and M. Das Role of the Adventitia in Pulmonary Vascular Remodeling Physiology, April 1, 2006; 21(2): 134 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Short, S. M. Fox, C. F. Lam, K. R. Stenmark, and M. Das Protein Kinase C{zeta} Attenuates Hypoxia-induced Proliferation of Fibroblasts by Regulating MAP Kinase Phosphatase-1 Expression Mol. Biol. Cell, April 1, 2006; 17(4): 1995 - 2008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ardanaz and P. J. Pagano Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Experimental Biology and Medicine, March 1, 2006; 231(3): 237 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Didion, D. A. Kinzenbaw, and F. M. Faraci Critical Role for CuZn-Superoxide Dismutase in Preventing Angiotensin II-Induced Endothelial Dysfunction Hypertension, November 1, 2005; 46(5): 1147 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Keaney Jr Oxidative Stress and the Vascular Wall: NADPH Oxidases Take Center Stage Circulation, October 25, 2005; 112(17): 2585 - 2588. [Full Text] [PDF]
|
|
|
|
|
|
R. M Touyz Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II Exp Physiol, July 1, 2005; 90(4): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Touyz, G. Yao, M.T. Quinn, P.J. Pagano, and E.L. Schiffrin p47phox Associates With the Cytoskeleton Through Cortactin in Human Vascular Smooth Muscle Cells: Role in NAD(P)H Oxidase Regulation by Angiotensin II Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Stenmark, N. J. Davie, J. T. Reeves, and M. G. Frid Hypoxia, leukocytes, and the pulmonary circulation J Appl Physiol, February 1, 2005; 98(2): 715 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Dourron, G. M. Jacobson, J. L. Park, J. Liu, D. J. Reddy, M. L. Scheel, and P. J. Pagano Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H946 - H953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Brandes and J. Kreuzer Vascular NADPH oxidases: molecular mechanisms of activation Cardiovasc Res, January 1, 2005; 65(1): 16 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Fernandez-Alfonso Regulation of Vascular Tone: The Fat Connection Hypertension, September 1, 2004; 44(3): 255 - 256. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Chen, J. F. Keaney Jr., E. Schulz, B. Levison, L. Shan, M. Sakuma, X. Zhang, C. Shi, S. L. Hazen, and D. I. Simon Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury PNAS, August 31, 2004; 101(35): 13014 - 13019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K K Griendling Novel NAD(P)H oxidases in the cardiovascular system Heart, May 1, 2004; 90(5): 491 - 493. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawahara, Y. Kuwano, S. Teshima-Kondo, R. Takeya, H. Sumimoto, K. Kishi, S. Tsunawaki, T. Hirayama, and K. Rokutan Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 1 in Oxidative Burst Response to Toll-Like Receptor 5 Signaling in Large Intestinal Epithelial Cells J. Immunol., March 1, 2004; 172(5): 3051 - 3058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Leite, A. Danilovic, P. Moriel, K. Dantas, S. Marklund, A. P. V. Dantas, and F. R.M. Laurindo Sustained Decrease in Superoxide Dismutase Activity Underlies Constrictive Remodeling After Balloon Injury in Rabbits Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2197 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Chamseddine and F. J. Miller Jr. gp91phox Contributes to NADPH oxidase activity in aortic fibroblasts but not smooth muscle cells Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2284 - H2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Taniyama and K. K. Griendling Reactive Oxygen Species in the Vasculature: Molecular and Cellular Mechanisms Hypertension, December 1, 2003; 42(6): 1075 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lassegue and R. E. Clempus Vascular NAD(P)H oxidases: specific features, expression, and regulation Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R277 - R297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin and R. M. Touyz Inflammation and Vascular Hypertrophy Induced by Angiotensin II: Role of NADPH Oxidase-Derived Reactive Oxygen Species Independently of Blood Pressure Elevation? Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 707 - 709. [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, F. Yang, X.-P. Yang, M. Jankowski, and P. J. Pagano NAD(P)H Oxidase Mediates Angiotensin II-Induced Vascular Macrophage Infiltration and Medial Hypertrophy Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 776 - 782. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||